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Abstract
Background: The goal of this study was to develop an in vivo-in vitro (IVIV) correlation, both in men and 
women, which allows constructing a model to predict bioequivalence assessments for drugs with narrow 
absorption windows. Besides, pharmacokinetic and pharmacodynamic equivalences were also investigated. 
Furosemide was chosen as a prototype.  
Methods: Twelve healthy Caucasian volunteers (8 women and 4 men) participated in a relative 
bioavailability study. Two oral formulations [Lasix® (Reference, R) and Furosemide EFA® (Test, T)] were 
administered under fasting conditions. Urinary excretion of unchanged drug (PK), and of chloride, sodium 
and potassium (PD) wasmonitored throughout time. PK and PD parameters were calculated from each 
respective excretion rate versus time curve. In vitro dissolution testing of both formulations was carried out 
using the USP apparatus 2 and 4 with fixed and variable dissolution media.
Results: T and R could be considered bioequivalent since the 90% confidence intervals for the T/R ratio of 
geometric means for the area under the urinary drug excretion rate versus time curve and for the maximum 
excretion rate were within the 0.80-1.25 bioequivalence interval. However, T had faster initial absorption 
and higher levels in women, while R displayed such characteristics in men. Closer IVIV correlations in 
women were obtained when apparatus 4 with variable biorelevant dissolution media were used [going 
from fasting state simulated gastric fluid to fasting state simulated intestinal fluid]. Since R had faster 
disintegration time than T, a shorter stay of R under gastric conditions was required in order to obtain a 
good IVIV correlation in men. Saluretic effect displayed a typical clockwise hysteresis loop for the PKPD 
correlation assessed through chloride-versus-furosemide urinary excretion rates. Even though a higher 
amount of furosemide was excreted with the urine in men, differences in the excretion of electrolytes 
between sexes were almost negligible.
Conclusions: Sex-differences in the gastrointestinal transit of formulations, under fasting conditions, 
determined the extent and the rate of furosemide absorption. The prolongation of the absorption process 
by mean of slowing the gastric emptying would make the formulation more effective. The USP-4 apparatus 
with variable dissolution media was able to discriminate the formulations even between sexes, becoming a 
promissory in vitro dissolution testing to predict bioequivalence.
Keywords: Furosemide, oral absorption, IVIV and PKPD correlations, sex-by-formulation interaction, 
bioequivalence
© 2016 Fagiolino et al; licensee Herbert Publications Ltd. This is an Open Access article distributed under the terms of Creative Commons Attribution License  
(http://creativecommons.org/licenses/by/3.0). This permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
Furosemide is a loop diuretic that is commonly used in the treatment 
of edematous states associated with cardiac, renal, hepatic failure 
and in the treatment of uncontrolled hypertension with abnor-
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mal renal function. Its oral bioavailability is low (67%) even if 
a solution of 40 mg is given to healthy male subjects [1]. In 
a study carried out with women and men [2], absolute bio-
availability under fasting state was reduced to 51% revealing 
a sex-related influence on the oral absorption of furosemide. 
Sustained-release formulations rendered even lower drug 
absorption [3,4]. Switching from intravenous bolus to oral 
slow release dosage forms, more than three quarters of the 
administered dose were not absorbed. Therefore, drug dissolu-
tion might play a significant role in furosemide absorption as 
it was previously reported [5,6]. Further extensive information 
about furosemide oral absorption and an appropriate back-
ground for this work can be found in Magallanes et al., 2015 [7]. 
Materials and methods
Equipment
GFL 2008 distillation apparatus (Germany) to provide distilled 
water, andOakton ph6 pH-meter (IL, United States) to adjust 
the pH of dissolution media were used.
To perform in vitro dissolution testing the following equip-
ment was used. USP apparatus 2 (paddle method): Distek® 
dissolution system 2100C equipment, configured with a 
model 89092EO Agilent peristaltic pump, and coupled with 
spectrophotometer Agilent 8453. A software ChemStation® 
CPU (Agilent) controlled all the dissolution testing. USP ap-
paratus 4: a Sotax CE 7 smart USP-4 flow through dissolution 
system connected to a Sotax CP-7 35 Piston Pump (Sotax, 
Switzerland), and collected samples assayed by a spectro-
photometer UV-Vis Thermo Spectronic, (model HeliosGamma, 
Thermo Scientific, UK).
When dissolution was under biorelevant condition the 
collected samples were assayed by HPLC system, consisting 
of an Agilent 1200 series binary pump (G1312A), an Agilent 
1200 series DAD detector (G1315D), an Agilent 1200 series 
autosampler (G1329A), an Agilent 1200 series controller 
(G1316A) and a Chemstation software (Agilent Technologies, 
Santa Clara, United States). The column was Thermo Hypersil 
BDS C18, 300Å, 250x4.6 mm, 5 μm.
In vitro disintegration times of formulations were measured 
with the USP disintegration apparatus (U.S. Pharmacopeial 
Convention, 2014) provided by local vendor (Tecnolab®), 
without disks. Individual disintegration times were manually 
recorded once dosage forms were completely broken down.
Furosemide urine concentrations were measured by high 
performance liquid chromatography coupled with ultravio-
let detector (HPLC-UV) with Dionex® Ultimate 3000 system 
equipped with a Phenomenex® Luna C18 reverse phase 
column (5 μm, 150x4.6 mm) kept at 40°C.
Electrolytes (chloride, sodium, and potassium) in urine were 
measured with Cobas c311 analyzer (Cobas® 4000 analyzer 
series, Roche/Hitachi).
Chemicals
Assayed formulations were two brands marketed in Uruguay 
as immediate-release tablets containing 40 mg of furosem-
ide: Furosemide EFA (Antia Moll, batch 028, expiration date 
Jan/2019, Test formulation [T]), and Lasix® (Sanofi Aventis, batch 
1D034M, expiration date May/2017, Reference formulation[R]). 
Furosemide powder used as standard was obtained from 
Antia Moll Laboratory.
Hydrochloric acid from Dorwil(Argentine) and potassium 
chloride from Carlo Erba(Milano, Italy) were used to prepare 
the simulated gastric (pH 2.2) fluid. Acetate buffer pH 4.6 
was prepared with glacial acetic acid and sodium acetate 
(Sigma-Aldrich [Dorset, England]) accordingly with USP-30. 
Fasted State Simulated Gastric Fluid (FaSSGF) and Fasted State 
Simulated Intestinal Fluid version 2 (FaSSIF-V2), whose com-
positions are informed elsewhere (Fotaki and Vertzoni, 2010), 
were prepared with the following ingredients:hydrochloric 
acid 36.5-38%, and pepsin (from porcine) from Sigma-Aldrich 
(Dorset, England); maleic acid, sodium chloride, and sodium 
hydroxide from Fisher Scientific UK Ltd. (Loughborough, Eng-
land), sodium taurocholate from Prodotti Chimici Alimentari 
S.P.A.(Basaluzzo, Italy); and egg lecithin - Lipoid EPCS from 
Lipoid GmbH(Ludwigshafen, Germany). Formic acid (from 
Sigma-Aldrich [Dorset, England]) and methanol HPLC-grade 
(from Merck (Darmstadt, Germany) were used for the prepa-
ration ofthe mobile phase for furosemide quantification in 
the samples from the in vitro biorelevant dissolution studies.
The organic solvents used for extraction of furosemide from 
the urine of volunteers (n-hexane [from Merck (Darmstadt, 
Germany)] and ethyl acetate [from Dorwil (Argentine)]) and 
for preparing standard solutions (methanol [from Pharmaco 
& Aaper (USA)]) were of analytical grade. Buffer prepared with 
potassium dihydrogen phosphate and phosphoric acid from 
Labsynth (Sao Paulo, Brazil), in adjunction with acetonitrile 
HPLC-grade (from Merck [Darmstadt, Germany]) was used as 
mobile phase for drug quantification in urine. The internal 
standard, phenytoin, was obtained from Fármaco Uruguayo 
Laboratory (Uruguayan pharmaceutical company).
In vitro disintegration at pH 2.5
Six units of each product were tested for disintegration ac-
cording to the United States Pharmacopoeia (USP30-NF35, 
physicochemical methods <701>) using the simulated gastric 
fluid without enzyme (aqueous solution of HCl and KCl, pH 2.5).
In vitro dissolution with USP-2 apparatus (pH 4.6)
Dissolution of six units of each formulation was performed in 
medium acetate buffer pH 4.6, at 37±0.5°C, volume 900 mL; 
stirring speed 50 rpm, sampling times: 5, 10, 15, 20, 30, 40, 
60, and 90 min. Quantification of furosemide concentrations 
in the dissolution samples was carried out by UV-absorption 
at 277 nm wavelength based on calibration curves in the 
dissolution medium.
In vitro dissolution with USP-4 apparatus 
Dissolution studies of the T and R formulations were performed 
Magallanes et al. Journal of Pharmaceutical Technology & Drug Research 2016, 
http://www.hoajonline.com/journals/pdf/2050-120X-5-2.pdf
3
doi: 10.7243/2050-120X-5-2
with the flow through system operating in the open mode 
at 37±0.5°C. A 5mm–size glass bead was positioned in the 
tip of the Ø 22.6mm cell, the cone was filled with 1mm–size 
glass beads and on the top of the cell a Whatman® glass fiber 
filter (GF/F: 0.7μm pore size) was placed. Formulations were 
placed on the tablet holder.
Dissolution at pH 4.6
The assay was carried out in medium pH 4.6 acetate buffer 
at 37±0.5°C. Flow rate was set at 16 mL/min in order to allow 
the formulation to be in contact through 60 minutes with 
approximately the same volume of solvent as in the USP-2 
assay (960 mL vs 900 mL). Samples were collected every 15 
minutes and quantified as it was indicated under the dissolu-
tion with USP-2 pH 4.6 section.
Dissolution in variable biorelevant media from-1.6-to-6.5 pHs 
Dissolution of furosemide from the formulations was monitored 
in triplicate using biorelevant media in order to simulate the in 
vivo dissolution of both formulations under fasted state [8,9]. 
Sequential change of both the dissolution medium and the 
flow rate was performed: from FaSSGF pH 1.6 at 8 mL/min for 
60 min to FaSSIF-V2 pH 6.5 at 4 mL/min for 90 min. Samples 
were collected every 15 minutes. Furosemide concentration 
in the dissolution sample was quantified by an HPLC method 
adapted from Sora et al., 2010 [10], using methanol:formic 
acid 0.1% (v/v) 60:40 as mobile phase, 0.8 mL/min as flow 
rate, 25°C as run temperature, 20µL as injection volume, and 
233nm as detection wavelength.
Subjects and in vivo study design
Twelve Caucasian healthy volunteers (eight women and four 
men) between 21 and 37 years old with mean body weight (SD) 
of 64 (5) and 77 (21) kg, respectively, were enrolled. The study 
was carried out with one tablet (40 mg) of the formulation T, or 
the formulation R, administered under fasting conditions with 
200 mL of water, in a randomized, two-period, two-sequence 
(TR and RT), balanced crossover design. A one-week washout 
period was kept between both administrations. The study 
protocol and informed consent form were designed accord-
ing to the ethical guidelines for human clinical research and 
were approved by the Institutional Ethics Review Commit-
tee of the Faculty of Chemistry (Uruguay). Written informed 
consent was obtained from all subjects before their entry in 
the study. The study was performed in the Bioavailability and 
Bioequivalence Centre for Medicine Evaluation, situated in ‘‘Dr. 
Juan J. Crottogini’’ Hospital (Montevideo, Uruguay).
Volunteers came to the Centre the first day of each week 
with an eight-hour overnight fasting period. Urine samples 
were collected before dosing and at 20, 40, 60, 80, 100, 120, 
140, 160, 180, 240, 300, 360, 420, 480, 600, and 720 min after 
dosing. The volume of urine was registered and two aliquots, 
one for electrolytes determination (chloride, sodium, potas-
sium) and the other for furosemide quantification, were 
stored until analysis, refrigerated (2-8°C) and frozen (-20°C) 
respectively. Standardized meals (lunch, tea, and dinner) were 
provided at 5, 8, and 12 h after dose administration. From 
40 to 180 min post-dose, and following each urine sampling, 
70 mL of rehydration fluid, prepared after water dilution of 
Rehidron®, was given to the subjects. From 3 h post-dose, 
volunteers were rehydrated with 100 mL of fluid every hour 
after each urine sample collection. The fluid contained 15 
mmol/L sodium, 4 mmol/L potassium, 13 mmol/L chloride, 
15 mmol/L glucose, 2 mmol/L citrate. 
Chemical analysis in urine
Quantification of furosemide in urine was carried out by HPLC, 
based on the method described by Abou-Auda et al., 1998 [11] 
with minor modifications. Briefly, the assay was a liquid-liquid 
extraction of furosemide (with n-hexane : ethyl acetate [50:50]) 
from the urinary matrix (250 µL) by the addition of 250µL of 
phosphoric acid 2.5M and 50 µL of a methanolic solution 
of internal standard (phenytoin, 40 µg/mL). Ten seconds of 
gentle agitation by vortex, separation of the organic phase, 
and evaporation until dryness under stream of nitrogen. 
Reconstitution of the residue was performed with mobile 
phase (buffer phosphate 0.02M pH 3.5 : acetonitrile [65:35]). A 
volume of 20 µL was injected onto the reversed-phase column 
and eluates were monitored at 230 nm. Retention times of 
analytes were: 5.5 min (furosemide) and 7.7 min (phenytoin). 
Linearity was assessed between 0.5 to 20µg/mL of furosem-
ide in urine. The lower limit of quantification was 0.5µg/mL, 
since intra-and-inter-day precision was below 20%, in terms 
of coefficient of variation, and accuracy. Otherwise, precision 
and accuracy was comprised between±15% and within the 
85-115% interval, respectively.
Chloride, sodium, and potassium electrolytes were measured 
accordingly with the instructions given by the manufacturers 
(Roche/Hitachi, package insert).
Pharmacokinetic (furosemide) and pharmacodynamic 
(electrolytes) analysis
The volume of urine was multiplied by furosemide and ions 
concentrations in urinary samples in order to obtain the amount 
of analyte (ΔA) in each interval of time (ΔT). By summing all 
ΔA, the total amount excreted in the urine of each analyte was 
obtained for the 12-hour study period (E0-12). Urinary excretion 
rates for each analyte (ER) were calculated dividing ΔA by ΔT 
and the result was assigned to the middle of the ΔT interval.
Urinary excretion rates of electrolytes were recorded as the 
pharmacodynamic responses (PDs) of the formulation given, 
and urinary excretion rate of furosemide as the corresponding 
pharmacokinetic response (PK). Non-compartmental PK/PD 
analysis for each analyte was performed over each ER versus 
time curve (Microsoft Office Excel 2007 software). The maxi-
mum ER (ERMAX) and the time-to-peak (TMAX) were recorded 
from experimental data for each volunteer and analyte. The 
area under the ER–time curve from zero to infinite (AUCINF), 
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for furosemide, was calculated using the trapezoidal rule 
until the last experimental time (AUC11-hour), and extrapolated 
to infinite adding the term ER11/kEL, being kEL the first order 
elimination rate constant calculated from the slope of the 
terminal log-linear ER-time regression of data. AUCINF corre-
sponds to the total amount of furosemide excreted in urine 
(EINF). Furosemide half-life (T1/2) was calculated as Ln(2)/kEL. 
Statistical analysis
ER versus time curves for both electrolytes and furosemide 
aregraphed as mean values±standard error (SE). However, 
electrolyte versus furosemide ERs are presented as mean 
values±standard error of the electrolyte only, since it is set 
to assess if the same pharmacokinetic response could be as-
sociated with different pharmacodynamic response. If there 
was a significant difference (p<0.05) between two excretion 
rates of the electrolyte, then a significant hysteresis for the 
PK/PD relationship was assessed.
Pharmacokinetic parameters for furosemide (ERMAX, E0-12, 
and EINF), in logarithmic scale, were processed by analysis 
of variance (ANOVA, Microsoft Office Excel 2007 software) 
considering subjects, sequences, periods and treatments as 
variation sources. Coefficient of variation (CV) of the ANOVA 
was calculated according to the equation (1):
       
With  being the residual variance of the ANOVA performed 
on the log-transformed parameters.
A T-Wilcoxon test was used to evaluate the T-R difference for 
TMAX, since a non-normal distribution was assumed. Average 
bioequivalence between T and R, considering all the subjects, 
was declared if the 90% confidence intervals (90% CI) for the T/R 
ratio of the geometric means for each parameter were within 
the range of 0.80-1.25, and TMAX did not differ significantly. 
 
In vitro/in vivo and pharmacokinetic/pharmacodynamic 
correlations
Since only two formulations were assayed, no mathematical 
correlation will be performed between the in vitro dissolu-
tion and in vivo pharmacokinetics of furosemide. Just visual 
comparisons between percentages dissolved in vitro and 
percentages of doses recovered in urine from both formula-
tions, in both male and female subjects, will be carried out.
Diuresis and/or electrolyte ER versus furosemide ER will be 
correlated in order to assessPK/PD relationship in both sexes.
Results
In vitro studies
Dissolutions carried out with the USP-2 apparatus revealed 
that formulation Tremaine at the bottom of the vessels up 
to its total dissolution, even though it dissolved faster than 
R. Reference disintegrated immediately it was plunged into 
the dissolution medium (pH 4.6). Disintegration in simulated 
gastric fluid (pH 2.2) was significantly different between the 
(Equation 1)
two formulations, with the formulation T having a higher dis-
integration time than the formulation R(180±10vs.22±2 sec).
Dissolutions performance of the two formulations under 
all conditions tested are presented in Figure 1. Dissolution of 
furosemide from T is faster and more complete than from R 
after 1h in the acetate buffer with USP-2 and USP-4 apparatus. 
In biorelevant conditions with USP-4 apparatus, a negligible 
dissolution is observed in simulated fasted state gastric con-
ditions for both formulations. Furosemide dissolves slightly 
faster from T in the first part of the simulated fasted state 
intestinal conditions, having a complete dissolution at the 
end of the experiment from both formulations. 
Figure 1. In vitro dissolution of tablets containing 40 
mg of furosemide (Lasix® [Reference] and Furosemide 
EFA® [Test]) using USP-2 pH 4.6 (upper), USP-4 pH 4.6 
(middle), and USP-4 variable biorelevant media (lower).
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In vivo pharmacokinetic and pharmacodynamic study
The mean ER of furosemide throughout time for both formula-
tions in all the subjects, in men, and in women are presented 
in Figure 2. Table 1 summarizes the mean pharmacokinetic 
parameters obtained.
Parameters for all electrolytes are summarized in Table 2. 
Since there was a highly significant linear correlation between 
ER of urine (diuresis) and ER of chloride (data not shown), 
this was selected as the PD response of formulations to be 
presented graphically (Figure 3). A clockwise hysteresis loop 
was evident in both sexes, being significant in women.
Bioequivalence between formulations
Table 3 summarizes the ANOVA results and 90% CIs for ERMAX 
and EINF in the total of individuals and in women. No signifi-
Figure 2. Mean (±S.E.) urinary excretion rate of furosemide 
following a 40-mg oral dose of Lasix® [Reference] and 
Furosemide EFA® [Test] administration to 12 healthy 
Caucasian subjects (upper) [4 men (middle) and 8 women 
(lower)] under fasting state.
Figure 3. Mean (±S.E.) urinary excretion rate of chloride versus 
mean urinary excretion rate of furosemide after a 40-mg oral 
administration of Lasix® [Reference] and Furosemide EFA® 
[Test] to 4 healthy men (upper) or 8 healthy women (lower) 
under fasting state.
cant difference between formulations was obtained for TMAX.
Considering the sex of individuals, E0-12, EINF and ERMAX differed 
significantly (p<0.01 in both formulations, mean and SE val-
ues in Table 1). Half-life calculated in men (average between 
formulations=2.07 h) was lower than that in women (aver-
age between formulations=2.24 h), but without a statistical 
significance.
Discussion
Sex-related differences in the gastrointestinal tract
Regarding the bioequivalence between formulations, T could 
be assessed as bioequivalent with R. The extent of absorption 
in the total subjects (men and women) was similar between 
both products as revealed by the 90% CI of EINF T/R geometric 
mean ratio being between 0.80 and 1.25. Similarly, the ab-
sorption rate of formulations was assessed as bioequivalent 
considering the T/R geometric mean ratio of ERMAX (see Table 3) 
and TMAX did not differed significantly. Figure 2 (upper panel) 
supports this average bioequivalence judgment.
However, when only women were considered, bioequiva-
lence could not be assessed because both EINF and ERMAX 90% CI 
of T/R ratios moved to the right and could not be included 
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TMAX (h)a ERMAX (µg/min) E0-12 (mg) EINF (mg) T1/2 (h)
T R T R T R T R T R
Male
1.33 1.00 116 133 16.0 16.1 16.3 16.7 2.02 2.12
[1.17-1.83] [0.5-1.17] [24.5] [24.2] [2.2] [2.3] [2.2] [2.5] [0.10] [0.09]
Female
1.17 1.17 72.2 64.6 9.80 8.97 10.4 9.49 2.26 2.21
[0.83-2.83] [0.83-2.17] [6.0] [7.6] [0.67] [0.92] [0.59] [0.91] [0.40] [0.36]
Total
1.17 1.17 86.9 87.3 11.9 11.4 12.4 11.9 2.18 2.18
[0.83-2.83] [0.5-2.17] [10.4] [13.1] [1.2] [1.4] [1.1] [1.4] [0.25] [0.23]
Table 1. Arithmetic means[± standard error] of pharmacokinetic parameters obtained in 12 healthy 
subjects (4 men and 8 women) after a single oral dose of 40 mg of furosemide from Test (T) or 
Reference (R) formulations.
Table 2. Arithmetic means [±standard error] of pharmacodynamic parameters obtained in 12 
healthy subjects (4 men and 8 women) after a single oral dose of 40 mg of furosemide from Test (T) 
or Reference (R) formulations.
aMedian and range is informed for TMAX
TMAX (h)a ERMAX (mmol/h) E0-12 (mmol)
T R T R T R
Male
Chloride 1.33 [0.83-1.83] 1.00 [0.50-1.17] 114 [17] 157 [18] 224 [18] 278[35]
Sodium 1.33 [0.83-1.83] 1.00 [0.50-1.17] 107 [18] 149 [15] 214 [31] 262 [30]
Potassium 1.50 [0.83-1.83] 1.17 [0.50-1.50] 12 [1.3] 14 [1.9] 47 [2.6] 50 [2.8]
Urine 1.33 [0.83-1.83] 1.00 [0.50-1.17] 15.7 [2.8]b 21.0 [2.3]b 2056 [251]c 2432 [120]c
Female
Chloride 1.00 [0.50-2.50] 0.83 [0.83-1.83] 120 [9.2] 116 [6.9] 213 [19] 198 [20]
Sodium 1.00 [0.50-2.50] 0.83 [0.83-1.83] 113 [10] 110 [7.7] 199 [18] 191 [20]
Potassium 1.50 [0.83-2.50] 1.50 [0.83-1.83] 13 [0.7] 13 [1.0] 44 [2.6] 44 [3.4]
Urine 1.00 [0.50-1.50] 0.83 [0.83-1.83] 17.0 [1.1]b 17.6 [1.2]b 2227 [179]c 2207 [208]c
Total
Chloride 1.17 [0.50-2.50] 0.83 [0.50-1.83] 118 [7.9] 130 [9.2] 216 [15] 225 [20]
Sodium 1.17 [0.50-2.50] 0.83 [0.50-1.83] 111 [8.6] 123 [8.7] 204 [15] 215 [19]
Potassium 1.33 [0.83-2.50] 1.17 [0.50-1.83] 13 [0.6] 13 [0.9] 45 [1.9] 46 [2.6]
Urine 1.17 [0.50-1.83] 0.83 [0.05-1.83] 16.6 [1.1]b 18.8 [1.2]b 2170 [141]c 2282 [144]c
aMedian and range instead of mean and standard error for TMAX
bExcretion rate of urine (mL/min); cVolume of urine (mL)
within the bioequivalence interval. Even though no confi-
dence intervals were constructed for male subjects, since 
only four individuals were enrolled, a faster beginning of 
drug absorption and a higher maximum excretion rate of 
furosemide from R, with similar-to-the-T amount of drug ex-
creted (see T-R relative values of TMAX, ERMAX and EINF in Table 1) 
was shown. This is contrary to the performance observed in 
women, and put in evidence that sexes might discriminate 
these formulations differently. Figure 2 (middle and lower 
panel) illustrates this statement.
The formulation R showed a faster in vitro disintegration 
time. If this is reproduced in vivo, the product would pursue 
Geometric mean Test Reference T/R IC 90% CV (%)
Total
EINF (mg) 11.9 11.1 1.08 0.98 1.18 12.1
ERMAX (µg/min) 81.4 77.7 1.05 0.90 1.22 21.3
Women
EINF (mg) 10.3 9.14 1.13 0.99 1.28 13.1
ERMAX (µg/min) 70.5 61.2 1.15 1.01 1.31 13.4
Table 3. Pharmacokinetic parameters of furosemide with their 
respective 90% confidence interval (90%CI) for the T/R ratio of 
means, and ANOVA coefficient of variations (CV), considering 
all the subjects (n=12) and the group of women (n=8).
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along the gastrointestinal tract following the individual 
physiologic transit. Conversely, T could have been retained 
for a longer time in the stomach of male subjects because 
gastric environment under fasting state is not so aggressive 
to provoke its rapid disintegration and thereafter its passage 
to the duodenum, since fluid content and stomach agitation 
are less intensive [12]. On the other hand, gastric emptying 
in female subjects is more prolonged than in male, thus, 
the formulation T would have enough time to disintegrate, 
making its passage to the duodenum be accomplished at 
the same time as R. Gastric emptying would only affect the 
time from which the drug starts its absorption through the 
intestinal membranes [13]. In the case of men, and for acidic 
drugs like furosemide, as their higher strength of gastric 
contraction promotes shorter intervals between each gastric 
discharge, the faster the formulation disintegrates, the faster 
its intestinal dissolution starts. Women, with longer intervals 
of gastric discharge, are unable to differentiate the passage of 
formulations from the stomach to the intestine even though 
they could have some differences in their disintegration times.
Therefore, a good correlation between the in vitro dissolution 
and the in vivo absorption of furosemide would be expected 
in women. Figure 4 displays similar in vitro/in vivo shapes for 
the cumulative T-R differences in dissolution and in urinary 
excretion of furosemide (upper and lower panel, respectively).
The use of sequential change of biorelevant media and 
physiological relevant flow rates with the flow through cell 
apparatus led to accurate predictions of the in vivo absorption 
of furosemide after oral administration of the two formulations 
(Figure 1). Clearly, not the apparatus, but the condition of the 
in vitro drug dissolution was the main cause for predicting 
accurately the in vivo absorption of formulations. The use of 
a compendial dissolution medium (acetate buffer pH of 4.6) 
with the paddle and the flow through cell apparatus was over 
discriminative. A change in the dissolution conditions passing 
from gastric to intestinal environment resulted more predic-
tive and realistic for woman subjects instead. Results obtained 
in men could be reproduced in vitro by simply shortening 
the gastric residence of the formulation R (Figure 5). In this 
way, the passage of the R granules to the duodenum, where 
furosemide dissolution is more effective and its absorption 
more efficient, was faster (Figure 2, middle panel).
In terms of the amount absorbed in both sexes, it can be 
seen that a similar amount of furosemide is absorbed from both 
formulations in man, whereas the fraction of dose absorbed 
from the two formulations is different in women. It is known 
that women have a more alkaline intestinal environment than 
men [14]. This finding explained the sex-related amount of 
ketoprofen absorbed from extended release formulations 
and the recirculation rate of its stereoisomers [15]. Accord-
ing to this, it could be hypothesized that women present a 
shorter absorption window for furosemide (pKa 3.8, [16]) in 
comparison with men (vertical line in Figures 4 and 5 repre-
sent the limit of time above which the absorption would be 
Figure 4. In vitro dissolution of tablets containing 40 mg of 
furosemide (Lasix® [Reference] and Furosemide EFA® [Test]) 
using the USP-4 apparatus with variable biorelevant media 
condition (upper) and in vivo mean (±S.E.) cumulative 
amount of furosemide excreted in urine following 40-mg 
doses in 8 healthy women (lower). Dashed line indicates the 
time to stop the dissolution assay in order to find in vitro-in 
vivo correlation.
negligible, in women and men respectively). For this reason, 
furosemide could be absorbed to the same extent from both 
formulations in men. Conversely, since the absorption of the 
drug drastically diminishes short time after its appearance 
into the intestinal tract of women, this sex could not allow R 
(slower dissolution rate) to be absorbed to the same extent 
as T (faster dissolution rate).
Sex-related differences in drug absorption and kidney 
blood perfusion
Diuretic (saluretic) effect of furosemide is the result of its con-
centration at the action sites in the ascending limb of the loop 
of Henle [17]. Arterial blood stream delivers the drug to the 
kidneys (glomerulus, proximal convoluted tubules and loop of 
Henle, among others sections of the nephron). One portion of 
the diffused amount in the renal parenchyma filters through 
the glomerular membrane. The other part enters the cells of 
the proximal tubule, of the ascending limb of loop of Henle 
that contain the saluretic action sites, and the other cells of 
the nephron. One fraction of this diffused amount returns to 
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the venous blood stream, while the complementary fraction 
pursues its renal excretion and metabolism (mainly from the 
proximal convoluted tubules). Venous blood collects the drug 
at the concentration it has in the interstitial space of the tissue. 
In the case of kidneys, this drug concentration is the one it 
had in the lumen of renal tubules before the current cycle of 
the circulatory system, mainly from the proximal tubule and 
the descending limb of the loop of Henle where reabsorp-
tion is maximal. In this scenario, and while drug absorption is 
proceeding, furosemide plasma concentration in the venous 
blood coming from the kidney would have lower value than 
in the arterial blood that reaches the organ. There will be a 
progressive reduction of the arterial-venous concentration 
difference throughout the absorption process up to the end 
of drug entrance. After this, the drug will only pursue its 
disposition throughout the body. Each time the absorption 
resumes, a new increase in the arterial-venous difference 
occurs. Theoretical and experimental research dealt with 
this physiological phenomenon and with its consequence 
Figure 5. In vitro dissolution of tablets containing 40 mg 
of furosemide (Lasix® [Reference] and Furosemide EFA® 
[Test]) using the USP-4 apparatus with variable biorelevant 
mediacondition and shorter gastric duration for the Reference 
(upper) and in vivo mean (±S.E.) cumulative amount of 
furosemide excreted in urine following 40-mg doses in 4 
healthy men (lower). Dashed line indicates the time to stop the 
dissolution assay in order to find in vitro-in vivo correlation.
on drug action [18,19].
According to this, furosemide would act before it could be 
excreted, since its arrival at the action sites from the capillar-
ies took lesser time than its arrival at the end of the luminal 
space of renal tubules from the glomerulus. For this reason, 
it is not surprising to observe a clockwise hysteresis loop for 
the relationships between chloride and furosemide ERs (see 
Figure 3). This resembles what was observed when drug effect, 
or arterial drug concentration, versus venous drug concentra-
tion was graphed for nicotine [19]. Accordingly, furosemide 
ERs would surrogate their venous plasma concentrations.
This finding was traditionally interpreted in the literature 
as an acute tolerance to the action of furosemide following 
single dose administration, mainly when extended release 
drug formulation or sustained intravenous administration 
were given [3,4,20-23]. As it was informed, no hysteresis or a 
counter-clockwise hysteresis was found after an intravenous 
bolus dose, revealing, this fact, that there would be a delay 
between drug concentration in venous blood and drug 
concentration at the action site (biophase), probably due to 
the extremely fast drug absorption, and thereafter absorp-
tion duration, in comparison with drug diffusion towards the 
tissue. However, when oral formulations were administered 
[3,4,20], drug release from the dosage form was slow enough 
to display such sequential steps in the arterial-biophase-
venous concentration. The slower the absorption process is, 
the wider the clockwise hysteresis loop becomes.
Our results clearly show a difference in the absorption time 
between sexes. As it can be seen in Figure 3 (upper panel), 
men displayed a more pronounced hysteresis loop after R than 
after T administration, even though both PK/PD loops have 
not reached significance (probably due to the low number of 
subjects). Once the formulation T passed to the duodenum, 
its rapid dissolution practically avoided the hysteresis loop. 
Conversely, repetitive passages of granules from R (tablet 
fragments) allowed the hysteresis loop to appear. Women 
slower gastric emptying increased the width of the hysteresis 
loop significantly (p<0.01), independently of the formulation 
given (Figure 3 lower panel). Therefore, furosemide absorption 
kinetics in women was governed by the gastric emptying, 
and not by the formulation.
As Figure 3 shows women and men do not have the same 
slope for the PK/PD relationship (see both graphs superim-
posed in the upper panel of Figure 6). Men had a slower slope.
It has been reported [24] that men have a higher percentage 
of cardiac output destined to the kidneys (19% vs 17%). So, 
a higher percentage of molecules in men (12%) are driven 
to the kidneys every blood circulation cycle, and then, their 
parenchyma would be additionally loaded with furosemide 
to an extent of 12% in relation to female subjects [25]. If the 
furosemide ERs were reduced by a factor of 1/1.12, drug ex-
cretion rate of men would be adapted to that of women. In 
other words, if plasma drug concentrations and kidney/blood 
concentration ratios were similar between women and men, 
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Figure 6. Superimposed graphs shown in Figure 3 (upper) 
and the effect of straightening just in men the furosemide 
urinary excretion rate by a factor of 0.80 (lower).
both PK/PD graph should have identical slope provided no 
difference in their pharmacodynamics would exist. However, 
even though this transformation was performed sex differ-
ences in the PK/PD slope persisted.
Up to now, we assumed that the pharmacodynamics of 
furosemide did not affect its pharmacokinetics, as if both PK 
and PD variables were independent. However, it should be 
born in mind that a higher renal blood flow fraction means 
not only higher drug concentration at the action site [26-28] 
but also at the luminal space of tubules, from where urinary 
excretion of furosemide will take place as a consequence of its 
own diuretic effect. So, a double contribution of such higher 
renal cardiac output should be considered to transform the 
furosemide ERs in men. Then, a straightening of 25% was 
applied on the furosemide ER axis (values multiplied by a 
factor of 0.80 [=1/1.25]), and the result can be seen in the 
lower panel of Figure 6. Now, a good PK/PD correlation was 
achieved regardless the sex of the individuals. This transfor-
mation simply means that men would have a 25% higher 
excretion renal clearance than women.
However, it should be kept in mind that the intensity of 
furosemide action is not linearly related with its concentration, 
and then, the assumption of a constant factor of 0.80 for the 
axis straightening should not be entirely appropriate. Renal 
excretion of furosemide might not be constant, as it is influ-
enced by its diuretic effect. No data about sex differences 
in the excretion renal clearance (CLexcr) of furosemide was 
published in the literature, but it seems reasonable to admit 
a higher renal clearance for men taking into account similar 
findings for other drugs or endogenous substances highly 
excreted in urine [29,30]. 
Actual sex-related differences in furosemide oral bio-
availability
Previous paragraph leads us to consider whether the urinary 
excretion of furosemide was reliable enough to assess oral 
bioavailability difference between sexes. Regarding the values 
of EINF from Table 1, a difference between 16.7 and 9.49 mg 
for the Reference seems too high in favor of men.
Taking into account that drug plasma concentration (C) 
and its urinary excretion rate (ER) are related by the equation 
2, ERMAX, E0-12, and EINF data for men, shown in Table 1, should 
be divided by a factor of 1.25 (man-to-women ratio of excre-
tion renal clearances) in order to be compared with those 
for women. 
     (Equation 2)
These transformed (for men) and non-transformed (for women) 
values (i.e., 13.4 mg [=16.7/1.25] and 9.49 mg for EINF, respec-
tively) would still maintain sex differences in bioavailability 
and other clearances apart from the excretion renal one. 
Assuming that only the bioavailability remained as source 
of variation, a women-to-men percentage for the absorbed 
dose would be 75%. So, a supplementary loss of 25% of the 
administered dose might be expected for women in relation 
with men, which could be caused by their higher intestinal 
pH and their shorter absorption window.Our estimation is 
now more in agreement with Waller et al., (1982) [1] and 
Hammarlund et al., (1984) [2] findings.
Conclusion
Men and women have dissimilar furosemide oral bioavail-
ability probably due to their differences in the intestinal 
pH, which in turn produces different absorption windows. 
The particular intestinal environment that women have was 
able to differentiate the extent of drug absorption of two 
immediate-release formulations marketed in Uruguay on 
the basis of their dissimilar drug dissolution. Conversely, in 
men drug was absorbed at the same extent because of the 
longer absorption window available for furosemide. Due to 
their faster gastric emptying, men were able to differentiate 
the beginning of drug absorption from both tablets, maybe 
because of their dissimilar disintegration times during the 
stay in the stomach. Even though both tablets could have 
been discriminated by women and men, they are assessed as 
average bioequivalent considering all the subjects. Minimal 
differences between formulations were detected both in 
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in vivo and in vitro assays, arriving to a good in vivo-in vitro 
correlation when the USP-4 apparatus under biorelevant 
conditions was used.
Similarly, the pharmacodynamics of both formulations was 
equivalent. Once again, different PKPD correlation related 
with the sex of individuals could be seen. Such sex differences 
might be explained on the basis of their different renal cardiac 
output distribution, which influenced their renal excretion 
as well. Because its diuretic effect, the pharmacodynamics 
of furosemide interacts with its own pharmacokinetics by 
increasing its renal excretion. Finally, the excretion rate of 
chloride is correlated with the excretion rate of furosemide, 
showing a clockwise hysteresis loop that relates to the rate 
of drug absorption. In the case of immediate-release dosage 
forms, the gastric emptying of individuals would control 
the width of the hysteresis loop more than the formulations 
themselves, as women and men showed.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions 
Acknowledgement
The first author of this work received a grant from 
the National Agency of Investigation and Innovation 
(ANII, POS_NAC_2014_1_102492) Uruguay, and from 
the Sectorial Commission for Scientific Research 
(CSIC, University of the Republic, Uruguay).
Publication history
EIC: James A. Radosevich, University of Illinois, USA.
Received: 27-Aug-2016 Final Revised: 28-Sep-2016 
Accepted: 08-Oct-2016 Published: 19-Oct-2016 
Authors’ contributions LM PF MV NF MI ML VB AB
Research concept and design ✓ ✓ ✓ ✓ -- -- -- --
Collection and/or assembly of 
data ✓ -- -- -- ✓ ✓ ✓ --
Data analysis and interpretation ✓ ✓ ✓ ✓ -- -- ✓ ✓
Writing the article -- ✓ ✓ ✓ -- -- -- --
Critical revision of the article -- ✓ ✓ ✓ -- -- -- ✓
Final approval of article -- ✓ ✓ ✓ -- -- -- --
Statistical analysis ✓ -- -- -- ✓ -- -- --
References
1. Waller ES, Hamilton SF, Massarella JW, Sharanevych MA, Smith RV, 
Yakatan GJ and Doluisio JT. Disposition and absolute bioavailability of 
furosemide in healthy males. J Pharm Sci. 1982; 71:1105-8. | Article | 
PubMed 
2. Hammarlund MM, Paalzow LK and Odlind B. Pharmacokinetics 
of furosemide in man after intravenous and oral administration. 
Application of moment analysis. Eur J Clin Pharmacol. 1984; 26:197-207. 
| Article | PubMed
3. Alvan G, Paintaud G, Eckernas SA and Grahnen A. Discrepancy between 
bioavailability as estimated from urinary recovery of frusemide and 
total diuretic effect. Br J Clin Pharmacol. 1992; 34:47-52. | Article | 
PubMed Abstract | PubMed FullText
4. Wakelkamp M, Blechert A, Eriksson M, Gjellan K and Graffner C. The 
influence of frusemide formulation on diuretic effect and efficiency. Br 
J Clin Pharmacol. 1999; 48:361-6. | Article | PubMed Abstract | PubMed 
FullText
5. Prasad VK, Rapaka RS, Knight PW and Cabana BE. Dissolution medium-A 
critical parameter to identify bioavailability problems of furosemide 
tablets. Int. J. Pharm. 1982; 11:81-90. | Article
6. McNamara PJ, Foster TS, Digenis GA, Patel RB, Craig WA, Welling PG, 
Rapaka RS, Prasad VK and Shah VP. Influence of tablet dissolution on 
furosemide bioavailability: a bioequivalence study. Pharm Res. 1987; 
4:150-3. | Article | PubMed 
7. Magallanes L, Lorier M, Ibarra M, Vázquez M, Fotaki N and Fagiolino P. 
A simple pharmacokinetic model based on mean residence times to 
predict furosemide exposure after oral doses. Int. J. Pharm. Pharm. Res. 
2015; 3:54-65. 
8. Jantratid E, Janssen N, Reppas C and Dressman JB. Dissolution media 
simulating conditions in the proximal human gastrointestinal tract: an 
update. Pharm Res. 2008; 25:1663-76. | Article | PubMed
9. Fotaki N and Vertzoni M. Biorelevant Dissolution Methods and Their 
Applications in In Vitro-In Vivo Correlations for Oral Formulations. The 
Open Drug Delivery Journal. 2010; 4:2-13. | Pdf
10. Sora DI, Udrescu S, Albu F, David V and Medvedovici A. Analytical issues 
in HPLC/MS/MS simultaneous assay of furosemide, spironolactone 
and canrenone in human plasma samples. J Pharm Biomed Anal. 2010; 
52:734-40. | Article | PubMed 
11. Abou-Auda HS, Al-Yamani MJ, Morad AM, Bawazir SA, Khan SZ and Al-
Khamis KI. High-performance liquid chromatographic determination of 
furosemide in plasma and urine and its use in bioavailability studies. J C
12. hromatogr B Biomed Sci Appl. 1998; 710:121-8. | Article | PubMed 
13. Hall JE. Guyton and Hall Textbook of Medical Physiology. 12th 
EditionPhiladelphia: Saunders. 2006. 
14. Fagiolino P, Vazquez M, Ibarra M, Magallanes L, Guevara N and Fotaki 
N. Sex- and smoke-related differences in gastrointestinal transit of 
cyclosporin A microemulsion capsules. Eur J Pharm Sci. 2014; 63:140-6. 
| Article | PubMed
15. Tuo B, Wen G, Wei J, Liu X, Wang X, Zhang Y, Wu H, Dong X, Chow JY, 
Vallon V and Dong H. Estrogen regulation of duodenal bicarbonate 
secretion and sex-specific protection of human duodenum. 
Gastroenterology. 2011; 141:854-63. | Article | PubMed Abstract | 
PubMed FullText
16. Lorier M, Magallanes L, Ibarra M, Guevara N, Vazquez M and Fagiolino 
P. Stereoselective Pharmacokinetics of Ketoprofen After Oral 
Administration of Modified-Release Formulations in Caucasian Healthy 
Subjects. Eur J Drug Metab Pharmacokinet. 2015. | Article | PubMed
17. Granero GE, Longhi MR, Mora MJ, Junginger HE, Midha KK, Shah VP, 
Stavchansky S, Dressman JB and Barends DM. Biowaiver monographs 
for immediate release solid oral dosage forms: furosemide. J Pharm Sci. 
2010; 99:2544-56. | Article | PubMed
18. Russell JM. Sodium-potassium-chloride cotransport. Physiol Rev. 2000; 
80:211-76. | Article | PubMed 
19. Fagiolino P, Vazquez M and Eiraldi R. Clearance and bioavailability study 
through arterio-venous drug concentrations relationship. Eur J Pharm 
Sci. 2013; 48:825-9. | Article | PubMed 
20. Gourlay SG and Benowitz NL. Arteriovenous differences in plasma 
concentration of nicotine and catecholamines and related 
cardiovascular effects after smoking, nicotine nasal spray, and 
intravenous nicotine. Clin Pharmacol Ther. 1997; 62:453-63. | Article | 
PubMed 
21. Klausner EA, Lavy E, Stepensky D, Cserepes E, Barta M, Friedman M and 
Hoffman A. Furosemide pharmacokinetics and pharmacodynamics 
following gastroretentive dosage form administration to healthy 
volunteers. J Clin Pharmacol. 2003; 43:711-20. | Article | PubMed 
22. Castaneda-Hernandez G, Verges J, Pichette V, Heroux L, Caille G 
and du Souich P. Input rate as a major determinant of furosemide 
pharmacodynamics: influence of fluid replacement and 
hypoalbuminemia. Drug Metab Dispos. 2000; 28:323-8. | Article | 
PubMed 
23. Louizos C, Yanez JA, Forrest ML and Davies NM. Understanding the 
Magallanes et al. Journal of Pharmaceutical Technology & Drug Research 2016, 
http://www.hoajonline.com/journals/pdf/2050-120X-5-2.pdf
11
doi: 10.7243/2050-120X-5-2
hysteresis loop conundrum in pharmacokinetic/pharmacodynamic 
relationships. J Pharm Pharm Sci. 2014; 17:34-91. | Article | PubMed 
Abstract | PubMed FullText
24. Yagi N, Kiuchi T, Satoh H, Terashima Y, Kenmotsu H, Sekikawa H and 
Takada M. Bioavailability and diuretic effect of furosemide following 
administration of tablets and retarded capsules to human subjects. Biol 
Pharm Bull. 1996; 19:616-22. | Article | PubMed 
25. Soldin OP, Chung SH and Mattison DR. Sex differences in drug 
disposition. J Biomed Biotechnol. 2011; 2011:187103. | Article | PubMed 
Abstract | PubMed FullText
26. Fagiolino P, Eiraldi R and Vazquez M. The influence of cardiovascular 
physiology on dose/pharmacokinetic and pharmacokinetic/
pharmacodynamic relationships. Clin Pharmacokinet. 2006; 45:433-48. | 
Article | PubMed 
27. Fagiolino P. The influence of cardiac output distribution on the tissue/
plasma drug concentration ratio. Eur J Drug Metab Pharmacokinet. 
2002; 27:79-81. | Article | PubMed 
28. Fagiolino P, Wilson F, Samaniego E and Vazquez M. In vitro approach 
to study the influence of the cardiac output distribution on drug 
concentration. Eur J Drug Metab Pharmacokinet. 2003; 28:147-53. | 
Article | PubMed 
29. Fagiolino P. Multiplicative dependence of the first order rate constant 
and its impact on clinical pharmacokinetics and bioequivalence. Eur J 
Drug Metab Pharmacokinet. 2004; 29:43-9. | Article | PubMed
30. Rosario MC, Thomson AH, Jodrell DI, Sharp CA and Elliott HL. Population 
pharmacokinetics of gentamicin in patients with cancer. Br J Clin 
Pharmacol. 1998; 46:229-36. | Article | PubMed Abstract | PubMed 
FullText
31. Cockcroft DW and Gault MH. Prediction of creatinine clearance from 
serum creatinine. Nephron. 1976; 16:31-41. | Article | PubMed
Citation:
Magallanes L, Fagiolino P, Vazquez M, Fotaki N, Ibarra M, 
Lorier M, Bertola V and Barindelli A. Sex-related in vitro/
in vivo and PK/PD correlations after oral single dose 
furosemide administration. J Pharm Technol Drug Res. 
2016; 5:2. http://dx.doi.org/10.7243/2050-120X-5-2
